Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells

Luo,Yunpeng; Che,Wen; Zhao,Mingyan

doi:10.3892/ijmm.2016.2828

Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells

Authors:
- Yunpeng Luo
- Wen Che
- Mingyan Zhao
View Affiliations

Affiliations: Department of Intensive Care Unit, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: December 13, 2016 https://doi.org/10.3892/ijmm.2016.2828
Pages: 297-306
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ulinastatin (UTI), a serine protease inhibitor, possesses anti-inflammatory properties and has been suggested to modulate lipopolysaccharide (LPS)-induced acute lung injury (ALI). High-mobility group box 1 (HMGB1), a nuclear DNA-binding protein, plays a key role in the development of ALI. The aim of this study was to investigate whether UTI attenuates ALI through the inhibition of HMGB1 expression and to elucidate the underlying molecular mechanisms. ALI was induced in male rats by the intratracheal instillation of LPS (5 mg/kg). UTI was administered intraperitoneally 30 min following exposure to LPS. A549 alveolar epithelial cells were incubated with LPS in the presence or absence of UTI. An enzyme-linked immunosorbent assay was used to detect the levels of inflammatory cytokines. Western blot analysis was performed to detect the changes in the expression levels of Toll-like receptor 2/4 (TLR2/4) and the activation of nuclear factor-κB (NF-κB). The results revealed that UTI significantly protected the animals from LPS-induced ALI, as evidenced by the decrease in the lung wet to dry weight ratio, total cells, neutrophils, macrophages and myeloperoxidase activity, associated with reduced lung histological damage. We also found that UTI post-treatment markedly inhibited the release of HMGB1 and other pro-inflammatory cytokines. Furthermore, UTI significantly inhibited the LPS-induced increase in TLR2/4 protein expression and NF-κB activation in lung tissues. In vitro, UTI markedly inhibited the expression of TLR2/4 and the activation of NF-κB in LPS-stimulated A549 alveolar epithelial cells. The findings of our study indicate that UTI attenuates LPS-induced ALI through the inhibition of HMGB1 expression in rats. These benefits are associated with the inhibition of the activation of the TLR2/4-NF-κB pathway by UTI.

View Figures

View References

1	Su CF, Kao SJ and Chen HI: Acute respiratory distress syndrome and lung injury: Pathogenetic mechanism and therapeutic implication. World J Crit Care Med. 1:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
2	Castellheim A, Brekke OL, Espevik T, Harboe M and Mollnes TE: Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol. 69:479–491. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jing H, Yao J, Liu X, Fan H, Zhang F, Li Z, Tian X and Zhou Y: Fish-oil emulsion (omega-3 polyunsaturated fatty acids) attenuates acute lung injury induced by intestinal ischemia-reperfusion through Adenosine 5′-monophosphate-activated protein kinase-sirtuin1 pathway. J Surg Res. 187:252–261. 2014. View Article : Google Scholar
4	Song Z, Zhao X, Gao Y, Liu M, Hou M, Jin H and Cui Y: Recombinant human brain natriuretic peptide ameliorates trauma-induced acute lung injury via inhibiting JAK/STAT signaling pathway in rats. J Trauma Acute Care Surg. 78:980–987. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lin WC, Chen CW, Huang YW, Chao L, Chao J, Lin YS and Lin CF: Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 5:124632015. View Article : Google Scholar : PubMed/NCBI
6	Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ and Wang H: Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: An updated review. Expert Rev Clin Immunol. 10:713–727. 2014. View Article : Google Scholar : PubMed/NCBI
7	Agalave NM and Svensson CI: Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain. Mol Med. 20:569–578. 2015.
8	Wang H, Ward MF and Sama AE: Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets. 18:257–268. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI
10	Lutz W and Stetkiewicz J: High mobility group box 1 protein as a late-acting mediator of acute lung inflammation. Int J Occup Med Environ Health. 17:245–254. 2004.PubMed/NCBI
11	Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 101:296–301. 2004. View Article : Google Scholar :
12	Ye C, Choi JG, Abraham S, Wu H, Diaz D, Terreros D, Shankar P and Manjunath N: Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci USA. 109:21052–21057. 2012. View Article : Google Scholar : PubMed/NCBI
13	van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 11:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
14	Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 290:C917–C924. 2006. View Article : Google Scholar
15	Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ and Billiar TR: Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med. 19:88–98. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hirata Y, Kurobe H, Higashida M, Fukuda D, Shimabukuro M, Tanaka K, Higashikuni Y, Kitagawa T and Sata M: HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. Atherosclerosis. 231:227–233. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX and Liu MH: Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol. 64:543–547. 2012. View Article : Google Scholar
18	Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, Fan S, Zhou H and Zheng J: Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol. 17:799–807. 2013. View Article : Google Scholar : PubMed/NCBI
19	Gao C, Li R and Wang S: Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg. 72:169–176. 2012.
20	Li W, Qiu X, Jiang H, Zhi Y, Fu J and Liu J: Ulinastatin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of AMPK/NF-κB pathway. Int Immunopharmacol. 29:560–567. 2015. View Article : Google Scholar : PubMed/NCBI
21	Huang N, Wang F, Wang Y, Hou J, Li J and Deng X: Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res. 182:296–302. 2013. View Article : Google Scholar
22	Shen W, Gan J, Xu S, Jiang G and Wu H: Penehyclidine hydrochloride attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Pharmacol Res. 60:296–302. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wang F, Meng Y, Zhang Y, Zhao G, Zheng X, Xiao Q and Yu Y: Ketamine reduces lipopolysaccharide-induced high-mobility group box-1 through heme oxygenase-1 and nuclear factor erythroid 2-related factor 2/p38 mitogen-activated protein kinase. J Surg Res. 194:599–613. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sung YH, Shin MS, Ko IG, Kim SE, Kim CJ, Ahn HJ, Yoon HS and Lee BJ: Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor-κB in BV2 mouse microglial cells. Int J Mol Med. 31:1030–1036. 2013.PubMed/NCBI
25	Feng G, Sun B and Li TZ: Daidzein attenuates lipopolysaccharide-induced acute lung injury via toll-like receptor 4/NF-kappaB pathway. Int Immunopharmacol. 26:392–400. 2015. View Article : Google Scholar : PubMed/NCBI
26	Tianzhu Z and Shumin W: Esculin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of TLR/NF-κB pathways. Inflammation. 38:1529–1536. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kawasaki T and Kawai T: Toll-like receptor signaling pathways. Front Immunol. 5:4612014. View Article : Google Scholar : PubMed/NCBI
28	Chang Y, Huang X, Liu Z, Han G, Huang L, Xiong YC and Wang Z: Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res. 181:308–314. 2013. View Article : Google Scholar
29	Liu Z, Zhang J, Huang X, Huang L, Li S and Wang Z: Magnesium sulfate inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated RAW264.7 macrophages in vitro. J Surg Res. 179:e189–e195. 2013. View Article : Google Scholar
30	Liu Z, Chang Y, Zhang J, Huang X, Jiang J, Li S and Wang Z: Magnesium deficiency promotes secretion of high-mobility group box 1 protein from lipopolysaccharide-activated macrophages in vitro. J Surg Res. 180:310–316. 2013. View Article : Google Scholar
31	Yang Q, Liu X, Yao Z, Mao S, Wei Q and Chang Y: Penehyclidine hydrochloride inhibits the release of high-mobility group box 1 in lipopolysaccharide-activated RAW264.7 cells and cecal ligation and puncture-induced septic mice. J Surg Res. 186:310–317. 2014. View Article : Google Scholar
32	Yamauchi Y, Izumi Y, Inoue M, Sugiura H, Goto T, Anraku M, Ohtsuka T, Kohno M, Soejima K and Nomori H: Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS One. 6:e290532011. View Article : Google Scholar
33	Inoue K and Takano H: Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs. 19:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
34	Maciejewski R, Burdan F, Burski K, Madej B, Ziemiakowicz R, Dabrowski A and Wallner G: Selected biochemical parameters and ultrastructural picture of pancreas due to Ulinastatin treatment of experimental acute pancreatitis. Exp Toxicol Pathol. 56:305–311. 2005. View Article : Google Scholar : PubMed/NCBI